A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries. by Mason, H et al.
A Cost Effectiveness Analysis of Salt Reduction Policies to
Reduce Coronary Heart Disease in Four Eastern
Mediterranean Countries
Helen Mason1*, Azza Shoaibi2, Rula Ghandour2, Martin O’Flaherty3, Simon Capewell3, Rana Khatib2,
Samer Jabr4, Belgin Unal5, Kaan So¨zmen6, Chokri Arfa7, Wafa Aissi8, Habiba Ben Romdhane8,
Fouad Fouad9, Radwan Al-Ali9, Abdullatif Husseini2,10, the MedCHAMPS project team
1 Yunus Centre for Social Business and Health, Glasgow Caledonian University, Glasgow, United Kingdom, 2 Institute of Community and Public Health, Birzeit University,
Birzeit, Palestine, Occupied Palestinian territory, 3Department of Public Health and Policy, Institute of Psychology, Health and Society, University of Liverpool, Liverpool,
United Kingdom, 4Department of Health Economics, Ministry of Health, Nablus, Palestine, Occupied Palestinian territory, 5Dokuz Eylu¨l University Faculty of Medicine,
Department of Public Health, I˙nciraltı- I˙zmir, Turkiye, 6Narlidere Community Health Center, Provincial Health Directorate of Izmir, Izmir, Turkey, 7 INTES/University of
Carthage, Tunis, Tunisia, 8Cardiovascular Disease Epidemiology and Prevention Research Laboratory, Faculty of Medicine, University Tunis El Manar, Tunis, Tunisia,
9 Syrian Center for Tobacco Studies, Aleppo, Syria, 10 Public Health Program, Department of Health Sciences, Qatar University, Doha, Qatar
Abstract
Background: Coronary Heart Disease (CHD) is rising in middle income countries. Population based strategies to reduce
specific CHD risk factors have an important role to play in reducing overall CHD mortality. Reducing dietary salt
consumption is a potentially cost-effective way to reduce CHD events. This paper presents an economic evaluation of
population based salt reduction policies in Tunisia, Syria, Palestine and Turkey.
Methods and Findings: Three policies to reduce dietary salt intake were evaluated: a health promotion campaign, labelling
of food packaging and mandatory reformulation of salt content in processed food. These were evaluated separately and in
combination. Estimates of the effectiveness of salt reduction on blood pressure were based on a literature review. The
reduction in mortality was estimated using the IMPACT CHD model specific to that country. Cumulative population health
effects were quantified as life years gained (LYG) over a 10 year time frame. The costs of each policy were estimated using
evidence from comparable policies and expert opinion including public sector costs and costs to the food industry. Health
care costs associated with CHDs were estimated using standardized unit costs. The total cost of implementing each policy
was compared against the current baseline (no policy). All costs were calculated using 2010 PPP exchange rates. In all four
countries most policies were cost saving compared with the baseline. The combination of all three policies (reducing salt
consumption by 30%) resulted in estimated cost savings of $235,000,000 and 6455 LYG in Tunisia; $39,000,000 and 31674
LYG in Syria; $6,000,000 and 2682 LYG in Palestine and $1,3000,000,000 and 378439 LYG in Turkey.
Conclusion: Decreasing dietary salt intake will reduce coronary heart disease deaths in the four countries. A comprehensive
strategy of health education and food industry actions to label and reduce salt content would save both money and lives.
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Introduction
Coronary heart disease (CHD) is rapidly increasing in middle
income countries, and by 2020 deaths are predicted to overtake
those from infectious diseases in all regions except Sub-Saharan
Africa [1]. This reflects an increase in major cardiovascular risk
factors, particularly rising levels of blood pressure, cholesterol,
obesity and diabetes as a consequence of changes in nutrition and
decreases in physical activity, compounded by high tobacco use.
The Eastern Mediterranean Region (EMR) has been recognised as
a hot-spot for CHD, where disease projections will exceed those of
other regions [1].
There is now a pressing need to develop population based
policies to reduce the burden of CHD. This was highlighted by the
UN High Level meeting on Non Communicable Diseases in
September 2011 [2], in particular, focusing on the key modifiable
risk factors including salt intake.
Diets high in salt increase blood pressure levels which is the
leading contributor to cardiovascular disease mortality [3].
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Decreasing dietary salt intake from 10 grams to 5 grams per day
could reduce cardiovascular diseases rate by 17% worldwide [4].
Dietary salt can come from two main sources: in the
preparation and serving of food at home, or through manufac-
turers adding it during the processing of the food products.
Strategies to reduce dietary salt intake therefore require a
combination of policies depending on which sources of salt
consumption are most prevalent within the specific country.
There are a number of potential policies governments can
introduce to reduce dietary salt intake. Health promotion
campaigns and labelling of food packaging with the salt content
can help to raise awareness and encourage individuals to reduce
salt consumption. Governments can also work with manufacturers
to encourage voluntary reformulation of processed food products
or go further and set mandatory regulations on the amount of salt
in processed food products. Fiscal policies like taxation of high salt
products might also be considered [5,6].
One of the most important considerations when deciding on
what salt reduction policy to adopt is cost effectiveness. Increasing
demands are being placed on health care systems around the
world as a result of aging populations and advances in expensive
technologies. Governments must therefore consider both the costs
and the benefits of all policies implemented. Such considerations
therefore become even more critical in low and middle income
countries where resources are particularly scarce.
There is increasing evidence on the cost effectiveness of these
salt reduction policies in high income countries [6,7]. In Australia,
one study concluded that reformulation of processed food either
through voluntary agreement between government and the food
industry or through mandatory regulations for industry was cost
saving; dietary advice alone was apparently not cost effective [8].
A Norwegian modelling study suggested that a combination of
policies including an information campaign, working with industry
to reduce salt in food products and taxation of high salt products
increased life expectancy and was cost saving [9]. Similarly a
modelling study in the US suggested that government collabora-
tion with manufacturers to reduce salt in processed food could gain
two million additional quality adjusted life years and annually save
over US$32 billion in medical costs [10].
However, much less research has been conducted in middle
income countries. These populations are often at different stages
within the epidemiological transition. Furthermore, their health
care systems face different resource constraints reducing the
applicability of the results from high income countries. Asaria et al
[11] modelled the cost effectiveness of a voluntary reduction in salt
content of processed food by manufacturers supported by a media
campaign in 23 low and middle income countries. Assuming that
this strategy would lead to a 15% reduction in salt intake, they
estimated 8.5 million deaths would be averted across the 23
countries over 10 years at a cost of between US$0.04 and US$0.32
per person per year depending on the country. Murray et al [12]
performed an analysis using selected WHO regions. They
evaluated two policies; voluntary agreements with manufacturers
and then mandatory legislation to reduce salt content in products.
For the EMR B region [13] (the focus of this paper) resulted in an
annual cost of PPP$54 per disability adjusted life year (DALY)
averted for the voluntary policy and PPP$27 per DALY averted
for the mandatory legislation. However both studies excluded
health care costs from the analysis making it difficult to make
direct comparisons between the results for low, middle and high
income countries.
Given this paucity of evidence, this paper presents the first
detailed study evaluating the cost effectiveness of a range of
policies to reduce dietary salt intake in four middle income
countries in the Eastern Mediterranean. Dietary salt intake in all
four countries is high (approximately 14 g per day in Tunisia,
Syria and Palestine and 18 g per day in Turkey). Therefore, there
is potential to have a substantial impact on salt intake. Our
evaluation used IMPACT, the most widely published CHD policy
model [14,15]. The IMPACT CHD model is a cell based
deterministic model which is comprehensive and includes all
patient groups, all standard treatments and all major risk factors. It
can be used to explain past trends in CHD and generate
predictions of future trends. Country specific IMPACT models
have been developed as part of the MedCHAMPS (MEDiterra-
nean studies of Cardiovascular disease and Hyperglycaemia:
analytical Modelling of Population Socio-economic transitions)
project [16]. These country specific models were used to evaluate
the potential health benefits and the cost effectiveness of different
salt reduction policies.
Methods
Potential policies for evaluation
A number of potential policies exist which might be imple-
mented to reduce dietary salt intake within the population. An
initial literature review suggested three contrasting policy options
with evidence of effectiveness: 1) a nationwide health promotion
campaign which would raise awareness and encourage people to
reduce their salt intake, 2) requiring manufacturers to clearly label
food products stating the salt content of the product to encourage
people to opt for lower salt levels, 3) mandatory reformulation
requiring manufacturers of food products to lower salt content.
Given that these policies could also be implemented in combina-
tion as well as individually, six permutations were considered for
evaluation (Table 1).
Effectiveness of different policies
A literature review was conducted to obtain estimates of the
effectiveness of each of the policies. In a step wise approach the
Table 1. Salt reduction policies for evaluation and estimated effectiveness of policy.
Policy Effectiveness [Range] Reference
Health promotion campaign 5% [1%–35%] [31]
Labelling of food packaging (labelling) 10% [5%–15%] [6]
Mandatory salt reduction of processed foods (reformulation) 10% [5%–40%] [10]
Health promotion campaign in conjunction with labelling of food packaging 15% [10%–20%] [11]
Health promotion campaign in conjunction mandatory salt reduction of processed foods 15% [15%–30%] [11]
All three policies in combination 30% [10%–50%] [32]
doi:10.1371/journal.pone.0084445.t001
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review was narrowed to include only studies reporting estimates of
the effectiveness of each of these policies, including evidence on
the effectiveness of the combined policies, on changing the
behaviour of the general population and not targeted at a specific
group. Databases searched included Medline, Embase and Econlit
(search strategy available in Supporting Information S1). Abstracts
were checked for studies which included effectiveness estimates for
any of the selected six policies. For each policy effectiveness
estimates which were considered to be the most recent and reliable
based on the outcomes of previous rigorous systematic reviews or
observed changes in population salt intake from large trials were
selected. To account for uncertainty around this value a minimum
and maximum effectiveness estimate was also included as a range
around this ‘best’ estimate. The final effectiveness values used in
the analysis and the references at which each estimate was based
on are presented in Table 1.
Health Outcomes
We extended the four country IMPACT CHD models [17,18]
to quantify the effect of the predefined salt reduction policies on
CHD mortality, and to estimate the resulting gain in life-years,
based on the method described by Unal and Fidan [19,20]. A
detailed description of the basic IMPACT Model is available in
Supporting Information S2.
First, we used the values resulting from our literature review as
estimates of the expected reduction of current sodium salt
consumption attributable to each given policy (Table 1). The
expected change in salt intake was then translated into a change in
mean population blood pressure based on the effects meta-
analysis estimates provided by He and McGregor [3]. The
resulting change in blood pressure was used to estimate the
number of deaths prevented or postponed (DPPs) in ten years (as a
predefined time frame), using the IMPACT CHD Policy model
beta approach, (see table S2.1 in Supporting Information S2) [21].
This was compared with the number of CHD deaths that would
have been expected if the CHD model death rates of the baseline
year continued (i.e. the ‘do nothing scenario’).
We then calculated the number of life-years potentially gained
by multiplying the estimated DPPs by the median survival for the
different subgroups within the population (diagnosed CHD,
undiagnosed CHD and population free of CHD). Estimates of
median survival were obtained from a previous analysis performed
for England and Wales for 1990–2000, based on large linked
population based datasets, and community based cohorts [22,23].
These were considered a reasonable historical proxy for current
median survivals in the countries analysed given the lack of local
longitudinal data [19,20]. A detailed description of the data
sources and quality is available in Supporting Information S2.
The reduction in numbers of CHD patients was calculated by
estimating the effect of the policy on hypertension prevalence
based on the shift of SBP and DBP distributions and assuming a
constant proportion of uncontrolled hypertension patients, and
estimating the change in attributable cases using a population
attributable risk fraction approach, using INTERHEART odds
ratio [24].
Costs
The cost data were split into three categories; 1) costs to the
public sector of introducing each policy, 2) costs to the private
sector of labelling packaging and reformulating food products 3)
the costs to the health services of treating people with CHD
The cost to the public sector associated with implementing the
health promotion campaign included promotional materials
(posters, leaflets, billboards) and publicity through television and
radio advertisements. These estimates were based on the cost of
previous health promotion campaigns within each country and
considered both material and human resources. We also assumed
that the labelling of packaging and the reformulation of food
products would generate a cost to the public sector to develop and
enforce a law to require producers to comply with the policy.
Table 2. Total Cost of implementing Policy (Excluding Health Care Costs) in PPP$.
Policy Tunisia Syria Palestine Turkey
health promotion campaign 101,407 331,690 47,593 5,287,500
labelling of food packaging (labelling) 44,067 180,648 47,153 118,772,305
Monitoring – labelling 22,963 163,269 12,808 1,680,229
Mandatory salt reduction of processed foods (reformulation) 113,988 96,166,052 9,622,631 197,009,853
Monitoring - reformulation 22,963 163,269 12,808 1,680,229
doi:10.1371/journal.pone.0084445.t002
Table 3. Unit Cost per patient for CHD Event in PPP$.
CHD Event Tunisia Syria Palestine Turkey
Acute AMI 14,273 381 2,333 1,975
Secondary prevention following AMI 1,145 118 595 604
Unstable Angina 11,285 51 1,062 3001
Chronic Angina 2,201 897 623 434
Chronic Heart Failure – treatment In hospital 3,429 129 342 594
Chronic Heart Failure –treatment in the community 394 269 465 180
Hypertension 204 55 212 67
doi:10.1371/journal.pone.0084445.t003
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These costs were obtained from official departments in each
country using a pre-tested standardized questionnaire. For the
costs to the private sector, the cost of labelling packaging with the
salt content and the cost to reformulate products were obtained
through an interview-based survey of selected manufacturers
within each country. We interviewed local producers of main food
items that were considered major sources of dietary salt such as;
dairy products, bakery, butter and margarines, pickles and salty
snacks. An estimate of the likely increase in production and
marketing costs of the reformulated/repackaged products in each
country was obtained. The total costs of implementing the health
promotion campaign, labelling of packaging, reformulation and
monitoring for each country are presented in Table 2.
Health care costs were considered using the IMPACT model.
The main CHD conditions were identified, these were: acute
myocardial infarction (AMI), secondary prevention after AMI,
unstable angina, chronic angina, heart failure admitted into
hospital and heart failure treated in the community) and
hypertension. For each CHD event a treatment package was
constructed including all drugs, procedures and associated medical
professional time. The costs of each of these items were obtained
from the Ministry of Health in each country based on typical
reimbursement rates. The IMPACT model includes the frequency
of use, uptake rates and patient numbers and from this the total
cost of the CHD event per patient could be calculated (Table 3
details the total cost per condition for each country).
All costs were collected in 2010 prices in local currency. To
allow for comparison between countries all costs were converted to
international dollars using purchasing power parity (PPP)
exchange rates.
Cost Effectiveness Analysis
A ten year time horizon was taken for the analysis. The total
cost of each policy option was calculated as the sum of the cost of
introducing the policy and the total CHD events related health
care costs over the 10 years. For the health promotion campaign, it
was assumed that the campaign would be repeated each year. For
the labeling and reformulation policies, it was assumed that there
would be an initial set up cost in the first year, but in the
subsequent years the only cost would be for monitoring to ensure
compliance. All future costs and outcomes were discounted at 3%
[25].
Each policy was compared against a baseline scenario of ‘doing
nothing’. For this scenario, the current number of CHD patients
was extracted from the IMPACT model and it was assumed that
broadly similar numbers of CHD patients would occur over the 10
year time frame. The incremental cost and LYG of each policy
over the baseline was calculated, and the incremental cost per
LYG for each policy was then elicited.
Sensitivity Analysis
Sensitivity analysis was conducted to assess the robustness of the
results. The uncertainty surrounding the effectiveness of the policy
to reduce population salt intake and its impact on total costs per
LYG was calculated using the minimum and maximum effective-
ness values extracted from the literature review (as shown in
Table 1).
Ethics Statement
An ethics statement was not required for this project.
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Results
All policies in all countries gained life years compared with the
baseline scenario. Table 4 gives the total discounted costs saved
(incremental costs), discounted cost per capita (incremental cost
per capita) and life years gained for each policy in the four
countries. A full set of results for each of the four countries,
including undiscounted values, are presented in Supporting
Information S3 (Tables S3.1–S3.4). In Tunisia, all policies were
cost saving apart from health promotion. In Syria, policies
involving health promotion and labelling were cost saving.
However reformulation costs were high therefore only the policy
which combined reformulation with health promotion and
labelling was cost saving. Furthermore, the incremental cost per
LYG of the policies which involved reformulation were all low
(below $5000). Similarly in Palestine, all policies were cost saving
apart from the reformulation using discounted costs. In Turkey all
policies were cost saving.
For policy purposes it is also important to know how the costs
incurred and costs saved are split between different sectors. In
Tables 5, 6, 7, 8, the total costs for each policy are disaggregated
into costs to the private sector, the non health care public/
governmental sector and the health service. The cost savings arise
through reductions in health service costs because of the reduced
number of CHD events compared with the baseline.
Sensitivity analysis was performed to calculate the total costs
and LYG assuming different levels of effectiveness. Using the
minimum and maximum effectiveness estimate for each policy (as
outlined in Table 1), the incremental cost and life years gained for
each policy in each country is presented in Tables 9, 10, 11, 12.
For the maximum estimates, all policies in all countries were cost
saving apart from the policy of reformulation combined with
health promotion in Syria.
For the minimum effectiveness estimates more policies incurred
an additional cost compared with baseline. In Tunisia, the
labelling and reformulation policies had an incremental cost per
LYG of $14,000 while for the health promotion policy the
incremental cost per LYG rose to over $150,000. In Syria, the
health promotion and labelling policies continued to be cost saving
but all other policies resulted in additional costs. In Palestine, the
three policies which involved reformulation were no longer cost
saving using the minimum effectiveness estimates but were still cost
effective. In Turkey, all policies were still cost saving.
Discussion
Reducing dietary salt intake across the population appears an
effective way of reducing coronary heart disease events and saving
substantial costs in each of these four middle income countries.
Three contrasting policies in six permutations were evaluated.
All of the policies resulted in a gain in life years compared with the
baseline of no intervention. The majority of the policies were cost
saving, with the biggest savings arising from a comprehensive
approach which combined labelling and reformulation with a
health promotion campaign. Even when a policy was not cost
saving it would still be regarded as cost effective according to
established cost effectiveness thresholds [25]. The cost savings
which arise from each of these policies stem from a reduction in
health care costs due to the potential reduction in the number of
CHD events. In this study we assumed that governments would
Table 9. Tunisia – Sensitivity Analysis.
Policy
Minimum Effectiveness
estimates, Costs saved*
Against Baseline ($PPP)
Minimum Effectiveness
estimates, Life Years
Gained
Maximum Effectiveness
estimates, Costs saved
Against Baseline ($PPP)
Maximum Effectiveness
estimates, Life Years
Gained
Health Promotion 264,733,792 233 277,608,378 7,431
Labelling 217,079,255 1,151 92,960,882 3,361
Reformulation 217,178,405 1,151 317,064,401 8,380
Reformulation + Labelling 92,591,889 3,361 235,999,378 6,455
Reformulation + Health Promotion 30,910,403 2,272 135,299,982 4,421
All 3 Policies together 38,090,450 2,272 385,132,741 10,202
*negative values indicates the incremental cost of the policy compared with baseline.
doi:10.1371/journal.pone.0084445.t009
Table 10. Syria – Sensitivity Analysis.
Policy
Minimum Effectiveness
estimates, Costs saved*
Against Baseline ($PPP)
Minimum Effectiveness
estimates, Life Years
Gained
Maximum Effectiveness
estimates, Costs saved*
Against Baseline ($PPP)
Maximum Effectiveness
estimates, Life Years
Gained
Health Promotion 217,972,286 1,149 162,360,949 36,426
Labelling 6,607,363 5,679 62,413,562 16,543
Reformulation 289,378,040 5,679 90,836,210 41,039
Reformulation + Labelling 235,149,960 16,543 42,029,664 31,674
Reformulation + Health Promotion 263,871,976 11,192 29,824,086 21,737
All 3 Policies together 265,450,094 11,192 130,384,153 49,866
*negative values indicates the incremental cost of the policy compared with baseline.
doi:10.1371/journal.pone.0084445.t010
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only be able to regulate local manufacturers of dairy, bread and
snack food products and not multinational food producers
importing food products into each of the four countries. This
assumption seemed reasonable as the market share for locally
produced dairy, bread and snack food products within each of
these countries is high. Furthermore, most international food
companies are continually reformulating their products to increase
competitiveness and maximise profits in a changing environment.
It is therefore likely that they are already reducing the salt content
of their food because many Western countries already have
voluntary policies to reduce salt in foods. If regulation was
introduced it would simply steer this existing process more rapidly
in a healthier direction, with minimal additional costs. The impact
on the public sector overall is likely to be favourable as spending
on the implementation of the policies would be offset against
reduced spending on health care.
The impact of each policy in terms of both costs and outcomes
is critically dependent on the assumed effectiveness of each policy
intervention in reducing salt intake. In Table 4, the costs and
outcomes reflect our ‘best’ estimate of effectiveness based on a
detailed review of the literature. However, recognising the
substantial uncertainties, a sensitivity analysis was conducted using
widely separated minimum and maximum effectiveness estimates.
For the maximum estimates, all policies in all countries were cost
saving (apart from the policy of reformulation combined with
health promotion in Syria), but these may overestimate the impact
of these polices. The results of the minimum effectiveness estimates
were more mixed. These represent a conservative account of what
might be achieved, and yet still suggest substantial benefits and
cost savings for many of the policies.
Our findings are consistent with those from high income
countries which generally report large health gains across the
population and cost savings, especially for policies involving
reformulation of food products [6]. This study is the first to take
the methodology previously applied in high income countries
(which includes costs to both the public and private sectors as well
as health care costs) and apply it to a middle income setting. It
extends the work of Asaria et al [11] and Murray et al [12] for
middle and low income countries which incorporated only the
costs of setting up and running the intervention by the public
sector and not the health care costs of treating CHD or costs to the
private sector. Considering only the public sector costs in this
study, the implementation of these six policy permutations would
cost between PPP $ 0.02–0.13 per person in Tunisia, PPP$0.07–
0.28 per person in Syria, PPP$0.03–0.15 per person in Palestine
and PPP$0.20–1.02 per person in Turkey. Such information is
reassuringly consistent with older studies, and might prove useful
for policy makers in each country.
The analysis in this study is confined to a ten year time horizon.
It does not take into account any health care costs postponed to
the distant future [26]. Future analysis might include future
unrelated health care costs, such as costs associated with
productivity gains from changes in work force participation or
changes in tax revenue following regulation, to give policy makers
a more accurate picture of the total resource use of a policy.
Furthermore, life time costs might also be lower [27].
Table 11. Palestine – Sensitivity Analysis.
Policy
Minimum Effectiveness
estimates, Costs saved*
Against Baseline ($PPP)
Minimum Effectiveness
estimates, Life Years
Gained
Maximum Effectiveness
estimates, Costs saved
Against Baseline ($PPP)
Maximum Effectiveness
estimates, Life Years Gained
Health Promotion 4,788,341 97 18,025,358 3,086
Labelling 7,085,509 479 11,570,459 1,398
Reformulation 22,489,969 479 9,995,219 3,479
Reformulation + Labelling 1,838,202 1,398 7,102,340 2,682
Reformulation + Health
Promotion
2532,604 945 87,146,361 1,838
All 3 Policies together 2689,383 945 11,627,340 4,232
*negative values indicates the incremental cost of the policy compared with baseline.
doi:10.1371/journal.pone.0084445.t011
Table 12. Turkey.
Policy
Minimum Effectiveness
estimates, Costs saved
Against Baseline ($PPP)
Minimum Effectiveness
estimates, Life Years
Gained
Maximum Effectiveness
estimates, Costs saved
Against Baseline ($PPP)
Maximum
Effectiveness
estimates, Life Years
Gained
Health Promotion 793,100,547 13,960 1,778,191,272 434,041
Labelling 861,383,222 68,816 1,203,473,919 199,303
Reformulation 783,145,674 68,816 1,714,028,326 487,712
Reformulation + Labelling 992,082,433 199,303 1,369,456,702 378,439
Reformulation + Health Promotion 920,237,425 135,221 1,214,365,624 261,147
All 3 Policies together 787,083,487 135,221 1,718,754,821 589,532
doi:10.1371/journal.pone.0084445.t012
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The methodology for the collection of cost data varies across
countries due to differences in availability of such data. This is a
limitation of the study and therefore we need to interpret
differences between the countries cautiously. However we did
make major efforts to maximise compatibility, and the general
findings appear robust. The effectiveness of each policy is based on
the values observed in relatively few other countries. We used the
most recent and robust estimates of effectiveness but also applied a
robust sensitivity analysis to provide a better view of the potential
minimum and maximum impact of these policies. The sensitivity
analysis was limited to the effectiveness estimates due to data
availability. Other model inputs such as the median survival were
not varied in the analysis; if data become available for any of the
specific countries this analysis could be repeated to improve the
applicability of the results to the local situation. The sensitivity
analysis we performed was not probabilistic due to the design of
the IMPACT models that were available for the countries. The
IMPACT model for each country was re-estimated using the
maximum and then minimum effectiveness estimated and the total
patient numbers for each CHD state and Life Years Gained was
used to calculate the total incremental cost per LYG for each
policy. The analysis assumes that the current (2010) level of CHD
rates in each country will continue for the ten year time frame.
Interestingly, age adjusted CHD mortality rates are rising in
Tunisia and Syria, but falling in Palestine and Turkey. Our results
may therefore underestimate the cost effectiveness of the policies in
Tunisia and Syria and over-estimate those in Palestine and
Turkey. Our cost effectiveness estimates may also be underesti-
mated because the cost of reformulation was obtained from the
manufacturers who may tend to exaggerate the true cost of
reformulation.
We chose the interventions which appeared promising in terms
of potential effectiveness. This was not a complete or comprehen-
sive list; more a useful selection of three contrasting approaches.
We also simplistically assumed a single step change in policy. In
reality implementation might be a phased over time as possibly
being easier for industry and for consumers (less likely to detect
progressive changes in salt content). Such phasing would slightly
delay achieving the full benefits. We also assumed that the demand
on the reformulated product will remain constant in the 10 years
period.
These cost effectiveness data produced in this paper provide an
important input into the decision making process. Implementation
of a salt reduction policy in each of the four countries will be
influenced by both the particular industrial environment as well as
the preferences of policy makers. Policies which involve health
promotion and labelling of food products may receive more
support being perceived as easier to implement. In Turkey and
Syria, manufacturers expressed concern about the reformulation
policy as they believe reduced salt products might not be
acceptable to consumers, mainly due to taste. In Palestine,
manufacturers appeared to be more amenable to reformulation
and policy makers preferred a one step programme of implemen-
tation as it was less costly, so that the combination of all 3 policies
might therefore be the recommended strategy.
This paper also may be considered to be contributing evidence
to the emerging field of nutrition economics which seeks to
evaluate the health and economic outcomes of nutrition based
interventions [28,29]. The understanding of the role nutrition
plays in public health will become increasingly important for
policy makers when deciding on how best to allocate scarce health
care resources especially the emphasis between preventative and
curative care. At present more evidence is needed which links food
consumption and the specific nutritional elements within that food
to longer term health outcomes. Salt consumption is one area in
which these links are already being made following longer term
studies such as the North Karelia Project in Finland [30]. If these
links can be established for other foods there is likely to be an
increased need to develop the field of nutrition economics as has
previously been done in health economics for curative treatments.
This study provides the first detailed evaluation of salt reduction
policies in four middle income Eastern Mediterranean countries.
The results powerfully reinforce the conclusions of previous studies
in high income countries demonstrating the cost effectiveness of
salt reduction policies. Decreasing dietary salt intake could
generate substantial health benefits in terms of life years gained
and cost savings.
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